Recently, the authors showed that the inhibition of CDK7-mediated transcription, through a more selective covalent inhibitor YKL-5-124, had synergistic effects when used in combination with JQ1 (BRD4 inhibitor), leading to reduced levels of MYCN expression and MYCN-associated oncogenes, the reduced proliferation of NB cells, and limited tumor growth in mice [110]. Here, CDK7 is linked to neuroblastoma.